Trial Profile
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Elismetrep (Primary)
- Indications Diabetic neuropathies; Neurological disorders; Vasomotor symptoms
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 05 Jan 2016 According to ClinicaTrials.gov record, status changed from recruiting to completed.
- 15 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 May 2015 New trial record